https://pipelinereview.com/two-phase-3-studies-of-the-triple-combination-of-vx-659-tezacaftor-and-ivacaftor-met-primary-endpoint-of-improvement-in-lung-function-ppfev1-in-people-with-cystic-fibrosis/